Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study

<table>Mean (± standard error) LVEF values in patients who did or did not receive trastuzumab.</table>

International Journal of Breast Cancer

fig3

Figure 3

Figure 3: Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study 

Figure 3 | Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study 